CO5090908A1 - Procedimiento para administrar peptidos insulinotropicos - Google Patents

Procedimiento para administrar peptidos insulinotropicos

Info

Publication number
CO5090908A1
CO5090908A1 CO99053457A CO99053457A CO5090908A1 CO 5090908 A1 CO5090908 A1 CO 5090908A1 CO 99053457 A CO99053457 A CO 99053457A CO 99053457 A CO99053457 A CO 99053457A CO 5090908 A1 CO5090908 A1 CO 5090908A1
Authority
CO
Colombia
Prior art keywords
managing
procedure
glp
insulinotropic peptides
administering
Prior art date
Application number
CO99053457A
Other languages
English (en)
Inventor
Lee Benjamin Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5090908(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5090908A1 publication Critical patent/CO5090908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procedimiento para administrar una molécula del péptido 1 similar al glucagón (GLP-1 ), procedimiento que comprende administrar por vía pulmonar una cantidad eficaz de una molécula de GLP-1, seleccionada del grupo formado por GLP-1, análogos del GLP-1 o derivados del GLP-1, a un paciente que lo necesite.
CO99053457A 1998-08-28 1999-08-24 Procedimiento para administrar peptidos insulinotropicos CO5090908A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11

Publications (1)

Publication Number Publication Date
CO5090908A1 true CO5090908A1 (es) 2001-10-30

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99053457A CO5090908A1 (es) 1998-08-28 1999-08-24 Procedimiento para administrar peptidos insulinotropicos

Country Status (21)

Country Link
EP (1) EP0997151B1 (es)
JP (1) JP2002523466A (es)
KR (1) KR20010073033A (es)
CN (1) CN1314818A (es)
AR (1) AR022368A1 (es)
AT (1) ATE347902T1 (es)
AU (1) AU764371B2 (es)
BR (1) BR9913284A (es)
CA (1) CA2341454A1 (es)
CO (1) CO5090908A1 (es)
CZ (1) CZ2001690A3 (es)
DE (1) DE69934380D1 (es)
EA (1) EA200100289A1 (es)
HR (1) HRP20010141A2 (es)
HU (1) HUP0103369A3 (es)
IL (1) IL141241A0 (es)
NO (1) NO20010982L (es)
PE (1) PE20001031A1 (es)
PL (1) PL346317A1 (es)
TR (1) TR200100600T2 (es)
WO (1) WO2000012116A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP1542712A2 (en) * 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
IL160917A0 (en) 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
CA2493478C (en) * 2002-08-01 2014-11-18 Mannkind Corporation Cell transport compositions and uses thereof
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
CA2549582A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
BRPI0514293B1 (pt) 2004-08-23 2022-07-19 Mannkind Corporation Sistema microparticulado para distribuição de droga
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
BRPI0616071B8 (pt) 2005-09-14 2021-05-25 Mannkind Corp métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo
LT1965823T (lt) * 2005-11-04 2016-10-10 Glaxosmithkline Llc Hipoglikeminių agentų skyrimo būdai
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
MX360812B (es) 2006-02-22 2018-11-16 Mannkind Corp Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
RU2650035C2 (ru) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11359267B2 (en) 2017-02-21 2022-06-14 Jfe Steel Corporation High-carbon hot-rolled steel sheet and method for manufacturing the same
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
UA72181C2 (uk) * 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1019031A4 (en) * 1997-07-18 2003-02-05 Infimed Inc BIODEGRADABLE MACROMERS FOR THE REGULATED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES

Also Published As

Publication number Publication date
CN1314818A (zh) 2001-09-26
DE69934380D1 (de) 2007-01-25
EP0997151A3 (en) 2000-09-20
AR022368A1 (es) 2002-09-04
EA200100289A1 (ru) 2001-10-22
CA2341454A1 (en) 2000-03-09
NO20010982D0 (no) 2001-02-27
EP0997151B1 (en) 2006-12-13
ATE347902T1 (de) 2007-01-15
NO20010982L (no) 2001-04-27
IL141241A0 (en) 2002-03-10
PL346317A1 (en) 2002-01-28
KR20010073033A (ko) 2001-07-31
HUP0103369A2 (hu) 2002-02-28
BR9913284A (pt) 2001-05-15
TR200100600T2 (tr) 2001-07-23
AU764371B2 (en) 2003-08-14
WO2000012116A1 (en) 2000-03-09
JP2002523466A (ja) 2002-07-30
EP0997151A2 (en) 2000-05-03
PE20001031A1 (es) 2000-10-12
AU5584199A (en) 2000-03-21
HUP0103369A3 (en) 2002-03-28
CZ2001690A3 (cs) 2002-04-17
HRP20010141A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
AR019818A1 (es) Un inmunoconjugado de miostatina.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
WO2000034331A3 (en) Analogues of glp-1
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
TWI262925B (en) GLP-1 analogues
PT915910E (pt) Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
IL146868A0 (en) A pharmaceutical composition containing an igf-i/igfbp-3 complex
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
AR008908A1 (es) Uso de loratadina y un descongestivo para preparar un medicamento para mejorar la funcion pulmonar de un paciente que padece asma
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
DK1069912T3 (da) Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
CO5150213A1 (es) Concentrado oral de sertralina
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR008154A1 (es) Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion.
SE9303068D0 (sv) New use
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
EP1359159A3 (en) Analogues of GLP-1
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
WO2003003971A3 (fr) Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
UY26735A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982593A (es) Nuevo metodo de tratamiento vi